{
  "docId": "019de071-41d7-735b-bdce-76898f0847d2",
  "docSlug": "eaafde7daeccaea38d88b7264ade91c5",
  "documentTitle": "Erasca | IPO Presentation Deck | 46 slides",
  "authorId": "erasca",
  "authorName": "Erasca",
  "documentKindSlug": "pitchdeck",
  "documentKindLabel": "Pitch deck",
  "sourceTypeSlug": "investment_bank",
  "sourceTypeLabel": "Investment bank",
  "presentationDate": "2021-07-01 00:00:00",
  "orientation": "landscape",
  "aspectRatio": 1.7777778,
  "pageNumber": 43,
  "pageCount": 46,
  "prevPage": 42,
  "nextPage": 44,
  "slideType": "product_demo",
  "function": "present_solution",
  "density": "dense",
  "nDataPoints": 4,
  "notes": "Slide 43 from Erasca pitch deck.",
  "elementsJson": null,
  "metadataConfidence": 1,
  "imagePath": null,
  "slideHref": "/slides/019de071-41d7-735b-bdce-76898f0847d2/43",
  "deckHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2",
  "deckJsonHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2.json",
  "deckAnchorHref": "/decks/019de071-41d7-735b-bdce-76898f0847d2#slide-43",
  "components": [
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.06,
        "y": 0.22
      },
      "kind": "chart",
      "text": "Brain Concentrations (10mg/kg, PO) comparing ERAS-801 and Erlotinib",
      "attrs": null,
      "subkind": "area",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "96a8314e-11c8-401b-b009-90192578df60",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.35,
        "w": 0.35,
        "x": 0.55,
        "y": 0.22
      },
      "kind": "image",
      "text": "Diagram of ERAS-12 EGFR D2/D3 bispecific antibody mechanism",
      "attrs": null,
      "subkind": "illustration",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "8247382a-2c45-4985-9655-3b68720cbab9",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.55,
        "y": 0.65
      },
      "kind": "list",
      "text": "Blockade of NSCLC cell line proliferation. Proprietary bispecific antibody. All approved EGFR mAbs target D3, not D2. EGFR D2 targeting antibodies expected to be more effective when EGF is overexpressed.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "58037d42-9c89-468e-b1d7-ce4f18b41f93",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.25,
        "w": 0.4,
        "x": 0.05,
        "y": 0.65
      },
      "kind": "list",
      "text": "High BBB penetration and good oral bioavailability. Orally bioavailable small molecule with high CNS exposure (3.7:1 brain:plasma). Kp,uu over 4x higher than approved EGFR's. Potently/selectively inhibited EGFR alterations for refractory GBM.",
      "attrs": null,
      "subkind": "bullet",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "cde69d48-f865-4bab-9432-1299e5fc772b",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.03,
        "w": 0.4,
        "x": 0.15,
        "y": 0.95
      },
      "kind": "source-note",
      "text": "1 Kp,uu is a measure of the ratio of unbound brain concentration to unbound plasma concentration",
      "attrs": null,
      "subkind": null,
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "59e83572-670a-472a-8a5c-77062d9447ec",
      "frameworkName": null,
      "frameworkSlug": null
    },
    {
      "bbox": {
        "h": 0.05,
        "w": 0.6,
        "x": 0.03,
        "y": 0.05
      },
      "kind": "title",
      "text": "Our EGFR franchise programs are highly differentiated",
      "attrs": null,
      "subkind": "headline",
      "toolName": null,
      "toolSlug": null,
      "confidence": null,
      "componentId": "17f8a773-7b5f-400a-9378-99bae05c29a2",
      "frameworkName": null,
      "frameworkSlug": null
    }
  ],
  "metrics": [],
  "tools": [
    {
      "name": "List presentation",
      "slug": "list-presentation",
      "agent": null,
      "layer": "slide",
      "matchId": "df1b67df-8a5d-4b10-88c8-bcbab04f5f85",
      "evidence": "list/bullet: High BBB penetration and good oral bioavailability. Orally bioavailable small molecule with high CNS exposure (3.7:1 brain:plasma). Kp,uu over 4x higher than approved EGFR's.",
      "confidence": 0.7
    }
  ],
  "frameworks": [],
  "arcBeats": [],
  "loops": [],
  "imagePathAlt": null,
  "thumbSrc": null,
  "thumbSrcAlt": null,
  "locked": true
}